Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

Aiko Nagayama, Leif W. Ellisen, Bruce Chabner, Aditya Bardia

研究成果: Review article査読

44 被引用数 (Scopus)

抄録

Antibody–drug conjugates (ADCs) are complex immunoconjugates designed to selectively deliver toxic small molecules preferentially to cancer cells. These immunoconjugates consist of a monoclonal antibody - directed to a tumor antigen - and a cytotoxic agent that is conjugated to the antibody via a molecular linker. Following the binding to a specific antigen on the surface of cancer cells, the conjugate is internalized and releases its cytotoxic payload to kill the malignant cell. ADCs that have gained regulatory approval from the US Food and Drug Administration (FDA) include brentuximab vedotin for CD30-positive Hodgkin’s lymphoma and trastuzumab emtansine for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Several other agents are in advanced stages of clinical development, including sacituzumab govitecan for breast cancer, mirvetuximab soravtansine for ovarian cancer, rovalpituzumab tesirine for lung cancer, depatuxizumab mafodotin for glioblastoma, and oportuzumab monatox for bladder cancer. This review provides an overview of the recent clinical experience with the approved, most advanced, and other promising candidates of ADCs for solid tumors, including a description of biology and chemistry of ADCs, drug resistance and biomarkers, and the future perspective on combination strategies with these new immunoconjugates.

本文言語English
ページ(範囲)719-739
ページ数21
ジャーナルTargeted Oncology
12
6
DOI
出版ステータスPublished - 2017 12月 1
外部発表はい

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究
  • 薬理学(医学)

フィンガープリント

「Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル